Editas Medicine (NASDAQ:EDIT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday, January 9th.
According to Zacks, “Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. “
Several other research analysts have also weighed in on the company. ValuEngine lowered Editas Medicine from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. BidaskClub lowered Editas Medicine from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Cowen reissued a “buy” rating on shares of Editas Medicine in a report on Tuesday, November 7th. Cann reissued a “hold” rating on shares of Editas Medicine in a report on Tuesday, November 7th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $28.00 price objective (up previously from $27.00) on shares of Editas Medicine in a report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company’s stock. Editas Medicine has an average rating of “Buy” and a consensus target price of $30.73.
Editas Medicine (NASDAQ EDIT) opened at $34.75 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 10.12 and a quick ratio of 10.12. Editas Medicine has a 52-week low of $13.12 and a 52-week high of $41.60. The firm has a market capitalization of $1,530.00 and a PE ratio of -10.73.
Editas Medicine (NASDAQ:EDIT) last issued its earnings results on Tuesday, November 7th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.04). Editas Medicine had a negative return on equity of 70.19% and a negative net margin of 1,127.03%. The firm had revenue of $6.28 million during the quarter, compared to analyst estimates of $2.66 million. During the same period in the previous year, the company earned ($0.59) earnings per share. The business’s revenue for the quarter was up 553.0% on a year-over-year basis. sell-side analysts anticipate that Editas Medicine will post -2.92 earnings per share for the current year.
In related news, CFO Andrew A. F. Hack sold 5,000 shares of the stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $24.81, for a total transaction of $124,050.00. Following the completion of the sale, the chief financial officer now owns 5,000 shares in the company, valued at approximately $124,050. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Katrine Bosley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $38.79, for a total value of $775,800.00. Following the sale, the insider now owns 1,354,431 shares of the company’s stock, valued at approximately $52,538,378.49. The disclosure for this sale can be found here. In the last three months, insiders have sold 76,315 shares of company stock worth $2,386,021. 19.40% of the stock is currently owned by insiders.
Large investors have recently made changes to their positions in the stock. IHT Wealth Management LLC bought a new stake in Editas Medicine during the 2nd quarter valued at approximately $107,000. Great West Life Assurance Co. Can boosted its stake in Editas Medicine by 519.9% during the 3rd quarter. Great West Life Assurance Co. Can now owns 4,959 shares of the company’s stock valued at $114,000 after purchasing an additional 4,159 shares during the period. Legal & General Group Plc boosted its stake in Editas Medicine by 308.4% during the 2nd quarter. Legal & General Group Plc now owns 8,654 shares of the company’s stock valued at $145,000 after purchasing an additional 6,535 shares during the period. Royal Bank of Canada boosted its stake in Editas Medicine by 4.1% during the 2nd quarter. Royal Bank of Canada now owns 9,364 shares of the company’s stock valued at $157,000 after purchasing an additional 372 shares during the period. Finally, Plancorp LLC bought a new stake in shares of Editas Medicine in the 4th quarter worth approximately $235,000. Hedge funds and other institutional investors own 64.07% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Downgrades Editas Medicine (EDIT) to Sell” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/05/editas-medicine-edit-downgraded-by-zacks-investment-research.html.
About Editas Medicine
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Get a free copy of the Zacks research report on Editas Medicine (EDIT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.